Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ulcerative Colitis (UC) confirmed on endoscopy
Moderately to severely active UC (Mayo Score 6-12)
May be receiving oral 5-aminosalicylate (ASA), oral corticosteroid, azathioprine, 6-mercaptopurine (MP), or methotrexate
Treatment failure with at least one of the following agents received: corticosteroids, immunomodulators, tumor necrosis factor-alpha (TNFα) antagonists, vedolizumab
You may not be if
Diagnose of Crohn's disease or indeterminate colitis
Pregnant or lactating females
Any chronic medical condition (including, but not limited to cardiac or pulmonary disease, alcohol or drug abuse)
Exhibit severe UC / clinically significant active infection
History of malignancy in the last 5 years
Clareo Health | Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis
